BNKL — Bionik Laboratories Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $1.73m
- $1.81m
Annual income statement for Bionik Laboratories, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 March 31st | C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.25 | 2.15 | 1.19 | 1.27 | 1.81 |
| Cost of Revenue | |||||
| Gross Profit | 1.62 | 1.26 | 0.924 | 0.953 | 0.99 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.7 | 27.2 | 14.5 | 11.2 | 6.63 |
| Operating Profit | -9.49 | -25.1 | -13.3 | -9.97 | -4.83 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.6 | -25 | -13.6 | -10.4 | -4.95 |
| Net Income After Taxes | -10.6 | -25 | -13.6 | -10.4 | -4.95 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.6 | -25 | -13.6 | -10.4 | -4.95 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.6 | -25 | -13.6 | -10.4 | -4.95 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.47 | -2.49 | -1.26 | -0.891 | -0.716 |